A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
Trial details
- Registry ID
- NCT07625280
- Phase
- Phase 3
The FDA approved Xywav (JZP258) on 21 Jul 2020.
Drug identity checked against registry records
Also recorded as JZP258
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHNCT07625280 | Jazz Pharmaceuticals | Phase 3 | Recruiting | 2027-12-23Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2020-07-21Day | Xywav | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA212690", "applicant_as_listed_by_fda": "JAZZ", "brand_names": ["XYWAV"], "active_ingredients": ["CALCIUM OXYBATE", "MAGNESIUM OXYBATE", "POTASSIUM OXYBATE", "SODIUM OXYBATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20200721", "matched_on": "drug name equals FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |